Please assess the completion status of the following clinical trial:

Trial Title: Study of Dupilumab in Adult Participants With Active Eosinophilic Esophagitis (EoE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key inclusion criteria:~1. Documented diagnosis of EoE by endoscopy prior to or at screening~2. History of on average at least 2 episodes of dysphagia (with intake of solids off anti-inflammatory therapy) per week in the 4 weeks prior to screening and on average at least 2 episodes of documented dysphagia per week in the weeks between screening and baseline; dysphagia is defined as trouble swallowing solid food, or having solid food stick, by participant report~3. Must remain on a stabilized diet for at least 6 weeks prior to screening and during the course of the study; stable diet is defined as no initiation of single or multiple elimination diets or reintroduction of previously eliminated food groups~4. Documented history of or presence of any of the following: allergic disease (e.g, allergic asthma, allergic rhinitis, atopic dermatitis (AD), or food allergies), peripheral eosinophil counts ≥0.25 GI/L, or serum total Immunoglobulin E (IgE) ≥100 kU/L~Key Exclusion Criteria:~1. Prior participation in a dupilumab (anti-IL-4R) clinical trial~2. Other causes of esophageal eosinophilia or the following diseases: hypereosinophilic syndromes, Churg-Strauss vasculitis, and eosinophilic gastroenteritis~3. History of achalasia, active Helicobacter pylori infection, Crohn's disease, ulcerative colitis, celiac disease, and prior esophageal surgery prior to screening~4. Any esophageal stricture unable to be passed with a standard, diagnostic, adult (9 to10 mm) upper endoscope or any critical esophageal stricture that requires dilation at screening~5. History of bleeding disorders or esophageal varices~6. Use of chronic aspirin, nonsteroidal agents, or anti-coagulants within 2 weeks prior to screening. Participants should not stop these agents solely to become eligible for entry into this study~7. Treatment with an investigational drug within 2 months or within 5 half-lives (if known), whichever is longer, prior to screening~8. Use of systemic corticosteroids within 3 months or swallowed topical corticosteroids within 3 months prior to screening~9. Use of inhaled (pulmonary or nasal) topical corticosteroids within 3 months prior to screening and during the study, except stable dose for at least 3 months prior to screening biopsy, which cannot be changed during the study~10. Treatment with oral immunotherapy (OIT) within 6 months prior to screening~11. Allergen immunotherapy unless on stable dose for at least 1 year prior to screening~12. Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study~Note: The list of inclusion/ exclusion criteria provided above is not intended to contain all considerations relevant to a participant's potential participation in this clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Dupilumab 300 mg QW (Type: EXPERIMENTAL): Participants received SC dupilumab 300 mg during the 12-week double-blind treatment phase. Participants received 2 injections (300-mg initial dose, followed by a 300-mg loading dose) on day 1, followed by weekly injections.
- Placebo (Type: EXPERIMENTAL): Participants received matching placebo once weekly (qw) during the 12-week double-blind treatment phase. Participants received 2 injections on day 1, followed by weekly injections.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete